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Abstract
Inhibitory receptors mediate CD8 T-cell hyporesponsiveness against cancer and infectious diseases. PD-1 and CTLA-4 have
been extensively studied, and blocking antibodies have already shown clinical benefit for cancer patients. Only little is
known on extended co-expression of inhibitory receptors and their ligands. Here we analyzed the expression of eight
inhibitory receptors by tumor-antigen specific CD8 T-cells. We found that the majority of effector T-cells simultaneously
expressed four or more of the inhibitory receptors BTLA, TIM-3, LAG-3, KRLG-1, 2B4, CD160, PD-1 and CTLA-4. There were
major differences depending on antigen-specificity, differentiation and anatomical localization of T-cells. On the other hand,
naive T-cells were only single or double positive for BTLA and TIM-3. Extended co-expression is likely relevant for effector T-
cells, as we found expression of multiple ligands in metastatic lesions of melanoma patients. Together, our data suggest
that naive T-cells are primarily regulated by BTLA and TIM-3, whereas effector cells interact via larger numbers of inhibitory
receptors. Blocking multiple inhibitory receptors simultaneously or sequentially may improve T-cell based therapies, but
further studies are necessary to clarify the role of each receptor-ligand pair.
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Introduction
Upon activation, T-cells upregulate several hundred genes
required for proper proliferation, differentiation and function of
effector and memory T-cells [1,2,3]. In parallel to activatory
receptors and pathways, T-cells also express several inhibitory
receptors [4,5]. These receptors mediate T-cell hyporesponsive-
ness and thus play a central role in preventing overwhelming T-
cell activation, immune pathology and autoimmunity, but also
destruction of cancer cells [6,7,8]. Generally, these receptors are
upregulated with progressive T-cell differentiation, with the
notable exception of BTLA, which is high on naive cells but
downregulated in memory and effector cells [9,10]. Therapeutic
blockade of inhibitory receptors (e.g. by using antibodies) can
augment T-cell functionality [11], which is even more pronounced
when two inhibitory receptors are blocked simultaneously
[8,12,13,14,15,16]. Blocking of individual inhibitory receptors
has now become a novel approach to treat cancer patients. In
March 2011, the FDA has approved the monoclonal anti-CTLA-4
antibody Ipilimumab for melanoma patients [17,18,19]. Another
anti-CTLA-4 antibody (Tremilimumab) [20] and anti-PD-1
antibodies are in clinical development [21].
Several further inhibitory receptors (CD160, KLRG-1, TIM-3,
2B4, BTLA and LAG-3) have been studied individually
[9,22,23,24,25,26]. In contrast, their co-expression has not yet
been investigated in greater detail in cancer patients. Multiple
inhibitory receptors have been implicated in the induction of T-
cell exhaustion, a state of T-cell hyporesponsiveness that is
frequently found in chronic viral infections [5,8,11,27]. We have
recently shown that functional T-cell deficiency in melanoma
metastases is associated with gene expression characteristics of
exhausted T-cells [1], with significant similarity to chronic/
protracted viral infection [4]. In accordance, individuals with
cancer show enhanced expression of inhibitory receptors [28,29].
Here we determined expression patterns by analyzing eight
inhibitory receptors on tumor-antigen specific CD8 T-cells. We
found that apart from BTLA and TIM-3 these receptors were
mostly undetectable on naive T-cells, but upregulated following
priming and differentiation. In addition, we found altered
inhibitory receptor expression patterns in CD8 T-cells analyzed
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directly after isolation from melanoma metastases. In parallel, we
studied the ligands of these inhibitory receptors, and found that
many of them are expressed by melanoma cells and/or in the
tumor stroma. The data suggest that inhibition of tumor-specific
CD8 T-cells is mediated by multiple inhibitory receptors and
depends on antigen-specificity, differentiation and anatomical
localization of T-cells.
Materials and Methods
Ethics statement
The clinical studies were designed and conducted according to
the relevant regulatory standards, and approved by the ethical
commission of the University of Lausanne and by Swissmedic.
Blood and tissue were obtained upon written informed patient
consent.
Clinical trials
Vaccinations were done in the context of three consecutive
clinical trials of the Ludwig Institute for Cancer Research
[30,31,32] with similar study designs, and the same treatment
schedule and primary endpoint, i.e. induction of cancer-specific T-
cell responses. HLA-A*0201+ patients with stage III/IV metastatic
melanoma received multiple monthly low-dose vaccinations s.c.
with 100 mg Melan-A/MART-1 peptide and with or without
CpG-ODN (500 mg of the oligonucleotide PF-3512676/7909;
provided by Pfizer/Coley Pharmaceutical Group, U.S.A.), emul-
sified in 300–600 ml IFA (Incomplete Freund’s Adjvuant, i.e.
Montanide ISA-51 provided by Seppic, France) as described
previously [30,32] or 3 times 500 mg peptides (NY-ESO-1,
MAGE-A10 and Melan-A) emulsified in IFA with or without
CpG-ODN [31].
Blood and lymph node cells
Peripheral blood was obtained from patients, and from A2+
healthy donors through the University Blood Transfusion Center
of Lausanne, Switzerland. Metastatic lymph nodes were obtained
from melanoma patients after 762 vaccinations, the last one at a
mean of 79 days before surgery. T-cells from tumor-infiltrated
lymph nodes (TILN) were prepared after finely mincing surgery
specimens. Mononuclear cells were purified by density gradient
using Lymphoprep (Axis-Shieldy) and immediately cryopreserved
in RPMI 1640 supplemented with 40% FCS and 10% DMSO.
Flow cytometry
Cells were analyzed directly ex vivo, i.e. without prior culturing.
Cells were stained using A2/EBV BMLF1280–288 (GLCTLVAML)
tetramer, A2/CMV pp65495–503 (NLVPMVATV) tetramer, A2/
Melan-A/MART-126–35A27L (ELAGIGILTV) tetramer, A2/NY-
ESO-1157–165 (SLLMWIITQA) tetramer and A2/MAGE-A10254–262
(GLYDGMEHL) tetramer. Melan-A-specific tetramers were
labeled with APC-eFluorH780 (eBioscience), EBV- and NY-
ESO-1-specific tetramers were labeled with PE-TexasRed (BD
Pharmingen) and CMV- and MAGE-A10-specific tetramers were
labeled with both APC-eFluorH780 and PE-TexasRed allowing
for individual analysis of T-cells specific for three epitopes in a
single sample. Inhibitory receptors were stained as described
previously [1]. Briefly, surface staining was performed on PBMC
magnetically enriched for CD8 T-cells (Invitrogen, purity
.95%), with antibodies specific for CD8-PacificBlue, CCR7-
PC7, CD45RA-APC-A700 and four inhibitory receptors for
‘‘staining 1’’, i.e. KLRG-1-A488 (provided by H. Pircher), TIM-
3-PE (R&D Systems), PD-1-PerCP-eFl710 (eBioscience) and
CD160-A647 (eBioscience), or three inhibitory receptors for
‘‘staining 2’’, i.e. LAG-3-FITC (Alexis Biochemicals), BTLA-PE
(BD) and 2B4-PE-Cy5 (BioLegend). Staining 2 was completed
with CTLA-4-APC (BD) in FACS buffer with 0.1% saponin, after
the cells had been fixed for 30 minutes at room temperature (1%
formaldehyde-buffer). LIVE/DEAD-Fixable-Aqua (Invitrogen)
was used as a dead cell exclusion marker and appropriate isotype
controls were used to define negative populations. Because of
limitations of available cell numbers, not all samples could be
analyzed by both staining 1 and staining 2. The gating strategy is
shown in Figure S1A. Magnetic enrichment for CD8+ cells in
addition with careful gating on the CD8+ cells allowed
minimization of contaminations by other cell populations such
as NK and NKT cells.
Melanoma cell lines were generated as described [33] and
grown in RPMI 1640 medium supplemented with 10% FCS.
Surface stainings were performed using antibodies specific for
CD48-FITC (BioLegend), CD80-PE-Cy7 (BD), CD86-APC-
Alexa700 (BD), HVEM-PE (BioLegend), PD-L2-APC (BioLe-
gend), PD-L1-PE-Cy7 (BD), E-cadherin-APC (BioLegend), HLA-
II-FITC (Abcam). In addition, a PE-coupled galectin-9 specific
antibody (BioLegend) was used for intracellular staining.
Data was acquired on a Gallios Flow Cytometer (Beckman
Coulter) and analyzed using FlowJo 9.1 (TreeStar). Analysis of co-
expression of inhibitory receptors was done with SPICE software
version 5.2 [34].
Immunohistochemistry
Consecutive paraffin sections (4 mM thick) were cut and mounted
on electrostatically precharged slides (Superfrost Plus, Menzel-
Gla¨ser). The sections were deparaffinized in xylene and rehydrated
through graded alcohols. After endogenous peroxidase quenching
(0.3%H2O2 in distilled water for 5 minutes), antigens were retrieved
by boiling the sections in 1 mM EDTA solution, pH 9.0, in a
pressure cooker for 3 minutes. Tissue sections were incubated for
1 hour at RT with an antibody specific for HLA-class II (Novus
Biologicals), CD80 (Novus Biologicals), CD86 (Novus Biologicals),
CD273 (Atlas Antibodies), CD48 (Abnova), galectin-9 (R&D
Systems), or HVEM (Alexis Biochemicals). After washing, tissue
sections were incubated for 30 minutes at RT with horseradish
peroxidase–conjugated anti-rat, anti-mouse or anti-sheep IgG
(Dako) and diaminobenzidine (Dako). Finally, the sections were
counterstained with hematoxylin and dehydrated through graded
alcohols and xylene. Immunohistological data of HVEM was
already published in ref. [9] and is shown here for completion.
Statistical calculations
Hierarchical clustering and principal component analysis (PCA)
was performed using the program R version 2.13.0. For
quantitative comparisons, Student’s t-test (two-sample two-tailed
comparison) or one-way ANOVA with Tukey post-test (multiple-
sample comparison) were performed with Prism 5.0 unless
otherwise noted. Co-expression pie charts were compared with
each other using 10’000 permutations calculated with the software
SPICE 5.2. p,0.05 was considered significant (* = p,0.05;
** = p,0.01; *** = p,0.001; ns = not significant).
Results
Inhibitory receptors are upregulated with CD8 T-cell
differentiation
By flow cytometry, we analyzed co-expression of the eight
inhibitory receptors CD160, KLRG-1, PD-1, TIM-3 (‘‘staining
1’’) and 2B4, BTLA, CTLA-4 and LAG-3 (‘‘staining 2’’)
depending on T-cell differentiation status. Peripheral blood
Multiple Inhibitory Receptors on Human CD8 T-Cells
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mononuclear cells (PBMC) were stained with antibodies specific
for these inhibitory receptors, as well as for CD8, CD45RA and
CCR7. We gated on CD8 naive (N), central memory (CM),
effector memory (EM) and effector memory CD45RA+ (EMRA)
cells defined by CCR7 and CD45RA expression (Figure 1A). Naive
cells were frequently BTLA positive and many of them also
expressed TIM-3 (Figure 1B and S1B). All other inhibitory receptors
were upregulated along with progressive differentiation. While
EMRA cells were frequently positive for 2B4, KLRG-1 and
CD160, they expressed less PD-1 and BTLA than EM cells. The
expression levels of LAG-3 and CTLA-4 were very low in all
subpopulations of CD8 T-cells. Analysis of co-expression patterns
of inhibitory receptors revealed that not only the overall
frequencies of inhibitory receptor expression increased with
differentiation, but also the variability of co-expression of multiple
inhibitory receptors (Figure 1C). While only negligible numbers of
N and CM cells co-expressed two to four of the inhibitory
receptors CD160, KLRG-1, PD-1 and TIM-3 (staining 1), roughly
half the EM cells and three quarters of the EMRA cells did so
(Figure 1C, upper panels). Co-expression of PD-1 and TIM-3 was
observed in only a small portion of the EM cells while co-
expression of TIM-3 and CD160 was present only in EMRA cells.
A slightly different picture was observed for staining 2 (2B4,
BTLA, CTLA-4 and LAG-3) (Figure 1C, lower panels). The highest
percentage of co-expression of these inhibitory receptors was
observed in EM cells, with roughly 50% of the cells positive for
2B4 and BTLA. While in naive cells BTLA was frequently
expressed alone, its expression in EM and EMRA cells was almost
exclusively together with 2B4.
Overall, these data show that inhibitory receptors are
progressively upregulated with differentiation, with the remarkable
exceptions of BTLA and TIM-3. This pattern of expression is in
agreement with a recent report investigating the expression of 2B4,
KLRG-1, CD160 and PD-1 together with CD127 and CD27 on
HCV-specific CD8 T-cells [5].
Co-expression of inhibitory receptors of tumor-specific
T-cells is influenced by vaccination
Despite their naive status, Melan-A specific T-cells can be
detected ex vivo using tetramers in PBMC from healthy donors
[35]. In melanoma patients, the frequency of these T-cells
increases occasionally with disease progression and/or after
vaccination without CpG-ODN. In sharp contrast, nearly all
patients show strongly increased T-cell frequencies when CpG-
Figure 1. Expression profiles of inhibitory receptors with differentiation. (A) CD8 T-cell subsets were defined depending on expression of
CCR7 and CD45RA, namely naive (N), central memory (CM), effector memory (EM) and effector memory RA+ (EMRA) cells. Gates used for inhibitory
receptor analysis are shown in the four quadrants. (B) Mean values of inhibitory receptor expression in relation to the differentiation status. Individual
values are shown in Figure S1B. n = 31 for ‘‘staining 1’’ (KLRG-1, TIM-3, PD-1 and CD160); n = 21 for ‘‘staining 2’’ (LAG-3, BTLA, 2B4 and CTLA-4); four
samples of staining 1 were from healthy donors, the remaining from melanoma patients. (C) Co-expression of KLRG-1, TIM-3, PD-1 and CD160
(staining 1) and of LAG-3, BTLA, 2B4 and CTLA-4 (staining 2). Colors of the pie arcs depict the expression of individual inhibitory receptors, while the
color in the pie depicts the number of co-expressed inhibitory receptors. p-values of the permutation test are shown in tables next to the
corresponding pie charts. Co-expression was analyzed with SPICE 5.2.
doi:10.1371/journal.pone.0030852.g001
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ODNs are used as vaccine adjuvant [32]. We have previously
shown that the type of vaccination impacts on the expression of
BTLA [9] and that tumor-specific T-cells after vaccination express
multiple inhibitory receptors [1]. To investigate expression
patterns of specific inhibitory receptors, we first compared the
naive Melan-A-specific cells from healthy donors to the total pool
of naive T-cells (Figure 1C and 2A). Most of the Melan-A-specific T-
cells from healthy donors did not express inhibitory receptors,
apart from BTLA and TIM-3. Therefore, they closely resembled
total naive T-cells (Figures 1C and 2A). Furthermore, Melan-A-
specific T-cells in melanoma patients before vaccination also
closely resembled total naive T-cells and Melan-A-specific T-cells
from healthy donors (Figure 2A). This is likely due to the fact that in
melanoma patients, spontaneously activated cells are usually
infrequent and only weakly activated [30].
Subsequently, we extended the inhibitory receptor analysis to
patients after vaccination with Melan-A peptide, with or without
the addition of CpG-ODN 7909 to the vaccine formulation
(Figures 2A and S2), and compared the data to the other two
conditions, i.e. healthy donors and melanoma patients before
vaccination. Interestingly, the four receptors KLRG-1, TIM-3,
PD-1 and 2B4 were all significantly upregulated on Melan-A
specific T-cells with vaccination, especially with CpG-ODN. On
the contrary, BTLA expression was significantly downregulated as
described previously [9]. Finally, CD160, LAG-3 and CTLA-4
were expressed at very low levels without significant differences
between the four conditions. Regarding simultaneous co-expres-
sion, the Melan-A-specific cells were more often positive for two or
more inhibitory receptors when CpG-ODN was used for
vaccination as compared to ‘‘without CpG-ODN’’. Especially
the population triple positive for KLRG-1, PD-1 and TIM-3 made
up more than 30% of all Melan-A-specific T-cells after vaccination
with CpG-ODN. Even though technical issues prevented us from
investigating the co-expression patterns between KLRG-1, PD-1
Figure 2. Inhibitory receptor expression by Melan-A specific CD8 T-cells depending on vaccination. (A) Co-expression of KLRG-1, TIM-3,
PD-1 and CD160, and of LAG-3, BTLA, 2B4 and CTLA-4 by Melan-A specific CD8 T-cells. Blood samples from healthy donors (HD) or from patients
before immunotherapy (before vacc.) or after peptide+IFA vaccination with or without CpG-ODN 7909 were enriched for CD8 T-cells using magnetic
beads. Melan-A-specific CD8 T-cells were identified by staining with CD8-specific antibody and tetramer. Positivity for inhibitory receptors was
defined respective to isotype controls. n = 4 for HD; n = 3 for before vacc.; n = 9 for after vaccination without CpG-ODN and n= 11 for after vaccination
with CpG-ODN. Colors of the pie arcs depict the expression of individual inhibitory receptors, while the color in the pie depicts the number of co-
expressed inhibitory receptors. Co-expression was analyzed with SPICE 5.2. p-values of the permutation test are shown in tables next to the
corresponding pie charts. (B) Hierarchical clustering based on co-expression data of the eight inhibitory receptors shown in A, including the four
differentiation subsets (N, CM, EM, EMRA) of total CD8 T-cells. (C) Mean expression and SD of four inhibitory receptors upregulated on Melan-A-
specific T-cells with vaccination. Data from HD and from patients before vaccination were pooled for the group without vaccination (no vacc.). n = 7
for no vacc.; n = 9 for vaccination with CpG-ODN.
doi:10.1371/journal.pone.0030852.g002
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and TIM-3 (staining 1) on one side, and 2B4 and BTLA (staining
2) on the other side, it is clear from this analysis that at least some
of those triple positive samples co-expressed BTLA and/or 2B4,
making them quadruple positive or more.
Confirming these observations, hierarchical clustering based on
the co-expression of the eight inhibitory receptors, showed that
Melan-A-specific T-cells from healthy donors or from patients
before vaccination were closely related to the total pool of naive
CD8 T-cells (N), which changed significantly after vaccination
where the Melan-A specific T-cells resembled EM and EMRA
cells (Figure 2B). Strong upregulation of KLRG-1, TIM-3, PD-1
and 2B4 (Figure 2C), and concomitant downregulation of BTLA
(Figure S2) was observed after vaccination, particularly when CpG-
ODN was used as adjuvant, emphasizing that vaccination may
have profound effects on inhibitory receptor expression.
The pattern of inhibitory receptor expression by Melan-
A-specific T-cells is similar to other self-specific T-cells but
differs from virus-specific T-cells
We have recently reported [1] that Melan-A-specific T-cells
expressed different patterns of inhibitory receptors compared to
virus-specific T-cells. Here we extended this analysis by including
BTLA (Figure S3A) and investigating the co-expression patterns of
Melan-A-, CMV- and EBV-specific T-cells. We observed that all
three antigen-specific T-cell populations resembled EM and
EMRA cells more than N and CM cells. However, tumor-specific
T-cells differed more from EM and EMRA cells than the virus-
specific cells both in a hierarchical clustering (Figure S3B) and in a
principal component analysis (Figure S3C). This intermediate
position of Melan-A-specific cells is mainly due to their expression
of TIM-3 and virtual absence of CD160 (Figure S3A and reference
[1]). Next, we investigated whether the peculiarities observed for
Melan-A-specific T-cells was a general feature of self/tumor-
specific T-cells. In the framework of our melanoma program, some
patients were vaccinated simultaneously with three different short
peptides derived from Melan-A, NY-ESO-1 and MAGE-A10
[31]. We could analyze four patients with ex vivo detectable CD8
T-cell responses against all three peptides. In contrast to the
differing patterns observed between Melan-A- and virus-specific
T-cells (Figure S3A), NY-ESO-1- and MAGE-A10-specific T-cells
showed patterns comparable to Melan-A-specific T-cells, with no
significant differences in any of the eight inhibitory receptors
(Figures 3 and S4). In addition, the Melan-A-specific T-cells from
these four patients were highly similar to the Melan-A-specific T-
cells from the first group analyzed (Figures S3A and S4). This
observation suggests that the particular expression pattern
observed in tumor-specific T-cells is either a general property of
self/tumor-specific cells, or else induced by vaccination.
Influence of the microenvironment on the expression of
inhibitory receptors
The tumor microenvironment may strongly influence protein
expression, including inhibitory receptors [1]. Therefore, we
compared T-cells from PBMC and tumor infiltrated lymph nodes
(TILN). We observed an upregulation of LAG-3, CTLA-4 and
TIM-3 and a downregulation of KLRG-1 and CD160 in total
CD8 T-cells obtained from TILN compared to blood (Figure 4A).
Since it is likely that many of those total CD8 T-cells from TILN
are tumor specific, our data suggest that they frequently express
inhibitory receptors such as CTLA-4, LAG-3, PD-1, TIM-3,
BTLA and 2B4.
Tumor-specific and non-tumor-specific T-cells in TILN may be
affected differently by the presence of tumor cells. Melan-A-
specific T-cells from TILN expressed much less KLRG-1 but
more TIM-3, LAG-3 and CTLA-4 than their counterparts from
the blood (Figure 4B, red and Figure S5A). We could not observe
significant differences in the expression of CD160, BTLA, 2B4 and
PD-1, although TILN derived CD8 T-cells have been shown to
express more PD-1 than in cells from the circulation [36]. Overall,
Melan-A-specific cells in TILN had a higher expression of
inhibitory receptors than cells from the blood. This observation
fits with our recent finding that Melan-A-specific T-cells from
TILN show an exhaustion profile, i.e. a gene expression profile
matching exhausted T-cells, associated with impairment of
cytokine production and enhanced expression of inhibitory
receptors [1].
To study the impact of the lymph node microenvironment on
non-tumor-specific T-cells, we analyzed EBV-specific T-cells from
TILN (Figure 4B, black and Figure S5B). These cells should not (or
less) be influenced by the presence of tumor cells in the metastatic
Figure 3. Expression of inhibitory receptors on self/tumor-specific T-cells. Expression of inhibitory receptors by Melan-A, NY-ESO-1 and
MAGE-A10-specific T-cells from a representative patient (LAU 1169). CD8 T-cells were enriched using magnetic bead sorting. Melan-A- (black), NY-
ESO-1- (green) and MAGE-A10- (blue) specific CD8 T-cells were identified by tetramer staining as described in the Materials and Methods section. An
isotype control (grey) is shown as reference.
doi:10.1371/journal.pone.0030852.g003
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lymph nodes, as they are not tumor-specific, whereas they may
interact with normal lymph node cells. Interestingly, we found a
modulation of inhibitory receptors on the surface of EBV-specific
T-cells in TILN as compared to blood (Figure 4B), in part similar to
Melan-A-specific T-cells. Specifically, we found a downregulation
of KLRG-1 and CD160 in TILN. Also for 2B4, we observed a
lower expression in TILN – the absolute difference was small but
nevertheless significant. On the contrary, both LAG-3 and CTLA-
4 were upregulated, mirroring Melan-A-specific T-cells. Notably
and in contrast to Melan-A-specific T-cells, there was no change in
the expression of TIM-3 on EBV-specific T-cells from TILN.
Overall, these results demonstrate a major influence of the
microenvironment on the expression of several inhibitory
receptors on total CD8 and on antigen-specific T-cells. Compared
to the blood, KLRG-1 downregulation goes hand-in-hand with
LAG-3 and CTLA-4 upregulation in TILN as compared to blood.
Other changes in surface expression, for example the upregulation
of TIM-3 in Melan-A-specific T-cells or the downregulation of
CD160 in EBV-specific T-cells are likely antigen-specific effects.
Several ligands for inhibitory receptors are expressed in
melanoma lesions
Binding of inhibitory receptors to their respective ligands
(Table S1) is probably necessary for inhibiting T-cell function. To
determine whether these ligands are expressed in melanoma
metastases, we performed immunohistochemical analysis on 16
to 18 paraffin-embedded tumor sections (Figure 5A). With one
exception, all tumors were infiltrated by CD8 T-cells (3/18
strongly and 14/18 moderately). Most tumors expressed
intracellular CD80 (100%), HVEM (93%) and CD86 (88%)
and 9/17 expressed at least one of the three ligands MHC class
II, PD-L2 and galectin-9 (Figure 5B). In contrast, only 2/17
tumor sections showed expression of E-cadherin. Eight tumors
were available for the analysis of the expression of all seven
ligands. All of these lesions expressed at least three and 3/8
expressed at least four of the seven tested ligands. Tumor
infiltrating lymphocytes not only interact with the tumor cells
themselves, but also with the stroma surrounding the tumor.
Hence, ligands of inhibitory receptors expressed in the tumor
stroma may also have a negative impact on lymphocyte function.
In the tumor microenvironment, we found cells expressing MHC
class II and secreted galectin-9 in most of the cases, and CD80
and PD-L2 in some cases (Figure 5B and data not shown). In
parallel, we analyzed 15 melanoma cell lines generated from
metastatic tissue from melanoma patients by flow cytometry.
Most cells showed surface expression of PD-L1, PD-L2, MHC II
and HVEM but not of CD48 (Figure 5C). Confirming our results
on paraffin sections, E-cadherin expression was infrequent on
melanoma cell lines, in line with the known E-cadherin
downregulation by metastatic tumor cells [37] and correspond-
ing to the diminished expression of KLRG-1 by CD8 T-cells
found in TILN (Figure 4). Seven cell lines were also analyzed for
intracellular expression. In contrast to the paraffin-sections, all
melanoma cell lines expressed intracellular galectin-9. 7/7 lines
expressed intracellular CD86, however, none of them showed
CD80 expression. Even though a large heterogeneity in the
expression of inhibitory receptor ligands was observed in tumor
sections and on melanoma cell lines, all samples expressed at
least some of these ligands, suggesting that this type of negative
regulation of T-cell function may often be relevant in the tumor
microenvironment.
Discussion
The extended upregulation of inhibitory receptors plays many
roles in the control of activated T-cells and in the prevention of
tissue damage by cytotoxic T-cells. Even though the signaling
cascades downstream of inhibitory receptors are likely to overlap,
their functions are not necessarily redundant. The fact that their
expression is differently regulated depending on the T-cell
activation status argues for distinct functions of different inhibitory
receptors.
Interestingly, T-cell differentiation impacts differentially on the
expression of individual inhibitory receptors. Only two of the eight
studied inhibitory receptors, i.e. BTLA and TIM-3 were clearly
detectable already at the naive stage (Figure 6). BTLA was highest
in naive cells and lowest in EMRA cells, and TIM-3 was
intermediate on both naive and EMRA cells and low on central-
and effector memory cells. Many genes are modulated along T-cell
differentiation [3,38]. Apparently, inhibitory receptors play
different roles depending on the differentiation status, and may
also influence memory versus effector cell differentiation [4,5,39].
Based on their expression pattern described here, BTLA and
TIM-3 are important already for naive T-cells, not excluding an
Figure 4. Expression of inhibitory receptors by CD8 T-cells
derived from blood and tumor-infiltrated lymph nodes (TILNs).
(A) Co-expression analysis of total CD8 T-cells. Colors of the pie arcs
depict the expression of individual inhibitory receptors, while the color
in the pie depicts the number of co-expressed inhibitory receptors. Co-
expression was analyzed with SPICE 5.2. n = 9/8 (TILN) and 31/17 (blood)
for staining 1 and staining 2 respectively. (B) Melan-A- (red) and EBV-
(black) specific CD8 T-cells. Positivity for the inhibitory receptor was
defined respective to isotype controls. Blood samples were from
patients vaccinated either with CpG-ODN or without CpG-ODN. n = 20/
21 (blood; Melan-A/EBV) and n= 9/6 (TILN; Melan-A/EBV) for staining 1;
n = 23/24 (blood; Melan-A/EBV) and n=8/5 (TILN; Melan-A/EBV) for
staining 2 except BTLA, and n= 8/7 (TILN; Melan-A/EBV) for BTLA.
doi:10.1371/journal.pone.0030852.g004
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important function in differentiated cells, while PD-1, CTLA-4,
KLRG-1, 2B4, LAG-3 and CD160 primarily modulate the
functions of differentiated T-cells.
In comparison to total CD8 T-cells, non-naive cells specific for
the tumor-antigen Melan-A show distinct expression patterns,
essentially with more TIM-3 and PD-1 and less CD160 (Figure 6).
Figure 5. Expression of ligands of inhibitory receptors in melanoma metastases and by melanoma cell lines. (A,B) Paraffin-embedded
tumor sections from 16 to 18 tumors were stained by immunohistochemistry for seven inhibitory receptors and CD8. (A) Representative stainings
(magnification6200) for each ligand investigated. (B) Summary of immunohistochemical stainings represented as percent of positive samples. Low
(,10%), intermediate (int; 10–50%) and high (.50%) expression is indicated in a color scale. infilt: infiltration of CD8 T-cells in tumor cell nests; sec:
secreted i.e. intra- and extracellular presence of galectin-9. (C) Summary of expression by melanoma cell lines on the surface or intracellular (ic) as
percent of positive cell lines.
doi:10.1371/journal.pone.0030852.g005
Figure 6. Schematic representation of inhibitory receptor co-expression according to differentiation status and physical location.
Naive cells express BTLA and TIM-3. After peptide vaccination, Melan-A specific T-cells upregulate KLRG-1, 2B4, TIM-3 and PD-1, while they
downregulate BTLA. Total CD8 T-cells upregulate similar inhibitory receptors, but less PD-1 and TIM-3. They also express CD160, which is not
expressed by tumor-specific T-cells. In TILN, both total CD8 T-cells, which are to a large extent tumor-specific, and Melan-A specific T-cells
downregulate KLRG-1 (and in total CD8 T-cells CD160) and concomitantly express more PD-1, LAG-3, TIM-3 and CTLA-4.
doi:10.1371/journal.pone.0030852.g006
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The particularities of inhibitory receptor co-expression on Melan-
A specific T-cells were induced after priming, as Melan-A-specific
T-cells from healthy donors expressed inhibitory receptors highly
similar to total naive T-cells. Potent priming, such as with CpG-
ODN 7909 induced upregulation of KLRG-1 and TIM-3, and
concomitant downregulation of BTLA [9] compared to less potent
priming in the absence of the TLR-9 agonist CpG.
Confirming our previous report [1], CD8 T-cells specific for the
viral-antigens BMLF1 (EBV) and pp65 (CMV) displayed a
different pattern of inhibitory receptors compared to cells specific
for tumor-antigens. Apart from their specificity, these differences
between viral- and tumor-specific T-cells could also be due to their
distinct genesis. Unlike EBV- and CMV-specific T-cells, Melan-A-
specific T-cells studied were induced by vaccination, and vaccine
components can have a direct impact on inhibitory receptor
expression as we exemplified by the use of CpG-ODN. Since we
could not test the influence of other adjuvants or vaccine
formulations, it remains unknown whether the effect of CpG-
ODN was particularly strong, which may well be the case given
the unusually strong T-cell activation promoted by CpG-ODN
[32]. For further characterization of vaccine-mediated effects, it
would be interesting to study vaccine induced anti-viral immune
responses. This could be done with yellow fever or small pox
vaccination, which are known to induce robust CD8 T-cell
responses [40,41]. Since these vaccines use live attenuated viruses
in contrast to the peptide vaccination used in our study, one may
find different patterns. However, it is possible that high inhibitory
receptor expression primarily depends on the capacity of vaccines
to generate effector cells, which is high for CpG-ODN adjuvanted
vaccines and for live vaccines.
Based on their high precursor frequencies [35], it has been
argued that Melan-A-specific T-cells are unusual and not
representative of other tumor-antigen-specific T-cells. However,
cells specific for NY-ESO-1 and for MAGE-A10, two other tumor-
antigen specific T-cell populations with lower precursor frequen-
cies, were comparable to Melan-A-specific T-cells regarding the
expression of inhibitory receptors, arguing that higher TIM-3 and
PD-1 expression and lower CD160 expression is a general feature
of self/tumor-specific T-cells.
Apart from antigen-specificity and the type of T-cell stimula-
tion, the microenvironment was also found to strongly influence
the expression of inhibitory receptors on CD8 T-cells. Tumor-
specific T-cells from TILN were lower in KLRG-1 expression but
higher in TIM-3, LAG-3 and CTLA-4 expression as compared to
cells with the same specificity in blood (Figure 6). Analysis of EBV-
specific T-cells in TILN revealed that the upregulation of LAG-3
and CTLA-4 (but not of TIM-3) and the downregulation of
KLRG-1 were at least partially due to the microenvironment in
the lymph node. To further investigate how much of this
regulation is induced by the tumor cells present and how much
is due to the microenvironment normally found in lymph nodes,
experiments utilizing normal lymph nodes and non-lymphoid
tumor metastasis or primary tumor samples are warranted.
Inhibition of T-cell functions depends on interactions of
inhibitory receptors with their ligands. Therefore we analyzed
whether the respective ligands are present in the tumor
microenvironment. In the majority of patients we found multiple
ligands, such as PD-L2, galectin-9, HVEM, MHC class II, CD86
and CD80, but not E-cadherin. The presence of these ligands
within a metastatic lesion together with the upregulation of the
inhibitory receptors on the tumor-specific CD8 T-cells fits well
with the previously described functional deficiency [42] and the
exhaustion profile exhibited by tumor-specific T-cells in metastatic
lesions [1]. However, the expression of several ligands was
primarily intracellular, leaving the questions open regarding
eventual low-level surface expression and functional impact.
Further studies are necessary to detail the exact contribution of
each receptor-ligand interaction [43].
In summary, we found that inhibitory receptor co-expression on
antigen-specific T-cells strongly depended on their differentiation
status, antigen-specificity and on the tumor microenvironment.
These data support the rational for therapeutic blocking of
multiple inhibitory receptors, with the aim to increase the potential
of antigen-specific T-cells to confer immunity to cancer and
infection.
Supporting Information
Figure S1 Gating strategy, and inhibitory receptor
expression in total CD8 T-cells. (A) Gating strategy.
Expression of inhibitory receptors was analyzed on total CD8+
T-cells, on naive, central memory, effector memory and effector
memory RA+ cells (based on CCR7 and CD45RA expression)
and on tetramer positive cells. Staining 1 and staining 2 each
contained four antibodies specific for four different inhibitory
receptors (upper histograms). Isotype controls were used as
negative controls (lower histograms). (B) PBMCs were enriched
for CD8 using magnetic beads. Naive (N), central memory (CM),
effector memory (EM) and effector memory RA+ (EMRA) cells
were defined by the expression of CCR7 and CD45RA. Positivity
for the inhibitory receptor was defined respective to isotype
controls. p-values represent the results of the one-way ANOVA
test.
(TIF)
Figure S2 Influence of priming on expression of inhib-
itory receptors. Samples from healthy donors (HD) or patients
before vaccination (before vacc.) or after peptide+IFA vaccination,
either with or without CpG-ODN, were enriched for CD8 using
magnetic beads. Melan-A-specific T-cells were identified using
CD8-specific antibody and tetramer as described in the Materials
and Methods section. Positivity for the inhibitory receptor was
defined respective to isotype controls. p-values represent the results
of the one-way ANOVA test.
(TIF)
Figure S3 Expression of inhibitory receptors on tumor-
and virus-specific CD8 T-cells. Samples from blood from
patients were enriched for CD8 T-cells using magnetic beads.
Melan-A-, CMV- and EBV-specific CD8 T-cells were identified
by staining with CD8-specific antibody and tetramers as
described in the Materials and Methods section. Positivity for
the inhibitory receptor was defined respective to isotype
controls. n = 11/14/9 for Melan-A-, n = 7/8/3 for CMV- and
n = 15/18/8 for EBV-specific T-cells (staining 1 / LAG3, 2B4 /
BTLA, CTLA-4). (B) Hierarchical clustering based on co-
expression of the eight inhibitory receptors shown in A,
including the four differentiation subsets (N, CM, EM, EMRA)
of total CD8 T-cells. (C) Principal Component Analysis based
on the same data as in (B). Ellipses represent the 80-percent
level of the population while the crosses indicate the mean of
each population. Melan-A-specific cells are represented as black
dots without the ellipse.
(TIF)
Figure S4 Expression of inhibitory receptors on self/
tumor-specific CD8 T-cells. PBMC from four patients were
enriched for CD8 T-cells using magnetic beads. Melan-A-, NY-
ESO-1- and MAGE-A10-specific CD8 T-cells were identified by
staining with CD8-specific antibody and tetramers as described in
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the Materials and Methods section. Positivity for the inhibitory
receptor was defined respective to isotype controls.
(TIF)
Figure S5 Influence of the microenvironment on ex-
pression of inhibitory receptors. Samples from patients
vaccinated either with (red) or without (black) CpG-ODN were
enriched for CD8 using magnetic beads. Melan-A-specific T-cells
were identified using CD8-specific antibody and tetramer as
described in the Materials and Methods section. Positivity for the
inhibitory receptor was defined respective to isotype controls.
(TIF)
Table S1 Inhibitory receptors and identified ligands.
For each of the eight inhibitory receptors investigated the known
ligands are listed.
(PDF)
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Supplementary Table 1 Inhibitory receptors and their respective ligands 
inhibitory 
receptor 
ligand  
inhibitory 
receptor 
ligand 
KLRG-1 E-cadherin  LAG-3 MHC-II 
TIM-3 galectin-9  BTLA HVEM 
PD-1 PD-L1 / PD-L2  2B4 CD48 
CD160 HVEM  CTLA-4 CD80 / CD86 	  
